Are the IRBs prioritizing reviews of submissions?

Last updated: 3.16.2020

Yes. We are doing additional triage of all submissions (except continuing reviews) and prioritizing as follows:

  • Initial reviews:

    • FDA treatment protocols (HDEs, e-uses)
    • COVID studies (see below)
    • Potentially therapeutic clinical trials
    • Applications with funding approval needs
  • Changes of protocol:

    • COVID-related changes
    • Safety-related changes
    • Changes to potentially therapeutic studies
    • Funding changes
  • Reportable events

    • COVID-related reports take priority

If you have urgent review needs not covered above, please contact the following:

Keywords:COVID-19, priority, coronavirus,   Doc ID:98896
Owner:Monica E.Group:Health Sciences IRBs
Created:2020-03-16 12:24 CDTUpdated:2020-03-16 12:58 CDT
Sites:Health Sciences IRBs
Feedback:  0   0